1e
19
1
49
2
2
18
1b
1d
18
2b
55
1d
2 29
1d
25
Alan R. Cohen
88
55
Emeritus Professor CE of Pediatrics (Hematology)
7
61
Department: Pediatrics
4
1
b
1d
46
Contact information
55
4
3
3
3
2
4
b
1f
55
The Children's Hospital of Philadelphia
41 34th & Civic Center Blvd.
Philadelphia, PA 19104-4399
26
41 34th & Civic Center Blvd.
Philadelphia, PA 19104-4399
2e
Office: 215-590-2766
32 Fax: 215-590-3050
24
89
32 Fax: 215-590-3050
24
Email:
COHEN@EMAIL.CHOP.EDU
12
COHEN@EMAIL.CHOP.EDU
13
Education:
21 7 BA c
3d Harvard University (magna cum laude), 1968.
21 9 M.D. c
33 University of Pennsylvania, 1972.
c
3
3
3
3
8a
Permanent link21 7 BA c
3d Harvard University (magna cum laude), 1968.
21 9 M.D. c
33 University of Pennsylvania, 1972.
c
2 29
21
1e
1d
24
2b
29
27
23
1f2 Goedert, J.J., Eyster, M.E., Lederman, M.M., Mandalaki, T., De Moerloose, P., White, G.C., Angiolillo, A., Luban, N.L.C., Sherman, K.E., Manco-Johnson, M., Preiss, L., Leissinger, C., Kessler, C.M., Cohen, A.R., DiMichele, D., Hilgartner, M.W., Aledort, L.M., Kroner, B.L., Rosenberg, P.S., Katzakis, A.: End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 100(5): 1584-1589, 2002.
16a Wanless, I.R., Sweeney, G., Dhillon, A.P., Guido, M., Piga, A., Galanello, R., Gamberini, M.R., Schwartz, E., Cohen, A.R.: Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 100(5): 1566-1569, 2002.
16f Kulkarni, R., Aledort, L.M., Berntorp, E., Brackman, H.H., Brown, D., Cohen, A.R., Ewing, N.P., Gringeri, A., Gruppo, R., Hoots, K., Leissenger, C., Peerlinck, K., Poon, M., Wong, W.: Therapeutic choices for patients with hemophilia and high-titer inhibitors. Amer J of Hemat 67: 240-246, 2001.
101 Cohen, A., Porter, J.B.: Transfusion therapy.in Disorders of Hemoglobin. Cambridge University Press, New York. Forget, B.G., Higgs, D.R., Nagel, R.L. Steinberg, M.H. eds. (eds.). 2001.
10e Fisher, M.J., Cohen, A.: Normal red blood cell indices and differential diagnosis of anemia, Fetal and Neonatal Secrets. Hanley & Belfus, Inc. Philadelphia. Polin, R.A., Spitzer, A.R. (eds.). 2001.
eb Cohen, A.R., Galanello, R., Piga, A., DiPalma, A., Vullo, C., Tricata, F.: Safety profile of the oral iron chelator deferiprone. Br J Heamatol 108: 305-312, 2000.
162 Vesley, S., Buchanan, G.R., Cohen, A., Raskob, G., George, J. : Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: Results of a survey of practicing pediatric hematology-oncology specialists. J Pediat Hematol Oncol 22: 55-61, 2000.
157 Wanless, I.R., Sweeney, G., Dhillon, A.P., Guido, M., Piga, A., Galanello, R., DeSanctis, V., Schwartz, E., Cohen, A.: Absence of deferiprone-induced hepatic fibrosis: A multi-center study. American Society of Hematology Annual Meeting, San Francisco, CA December 2000.
12e Cohen, A.R., Galanello, R., Piga, A., Gamberini, R., DeSanctis, V., Tricta, F.: Long-term safety and efficacy of the oral iron chelator deferiprone (Presentation). American Society of Hematology, San Francisco, CA December 2000.
2c
7
1d
1f
Selected Publications
11e Wang, Z.J., Haselgrove, J.C., Martin, M.B., Hubbard, A.M, Li, S., Loomes, K., Moore, J.R., Zhao, H., Cohen, A.R.: Evaluation of iron overload by single voxel MRS measurement of liver T2. JMRI 15(4): 395-400, 2002.1f2 Goedert, J.J., Eyster, M.E., Lederman, M.M., Mandalaki, T., De Moerloose, P., White, G.C., Angiolillo, A., Luban, N.L.C., Sherman, K.E., Manco-Johnson, M., Preiss, L., Leissinger, C., Kessler, C.M., Cohen, A.R., DiMichele, D., Hilgartner, M.W., Aledort, L.M., Kroner, B.L., Rosenberg, P.S., Katzakis, A.: End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 100(5): 1584-1589, 2002.
16a Wanless, I.R., Sweeney, G., Dhillon, A.P., Guido, M., Piga, A., Galanello, R., Gamberini, M.R., Schwartz, E., Cohen, A.R.: Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 100(5): 1566-1569, 2002.
16f Kulkarni, R., Aledort, L.M., Berntorp, E., Brackman, H.H., Brown, D., Cohen, A.R., Ewing, N.P., Gringeri, A., Gruppo, R., Hoots, K., Leissenger, C., Peerlinck, K., Poon, M., Wong, W.: Therapeutic choices for patients with hemophilia and high-titer inhibitors. Amer J of Hemat 67: 240-246, 2001.
101 Cohen, A., Porter, J.B.: Transfusion therapy.in Disorders of Hemoglobin. Cambridge University Press, New York. Forget, B.G., Higgs, D.R., Nagel, R.L. Steinberg, M.H. eds. (eds.). 2001.
10e Fisher, M.J., Cohen, A.: Normal red blood cell indices and differential diagnosis of anemia, Fetal and Neonatal Secrets. Hanley & Belfus, Inc. Philadelphia. Polin, R.A., Spitzer, A.R. (eds.). 2001.
eb Cohen, A.R., Galanello, R., Piga, A., DiPalma, A., Vullo, C., Tricata, F.: Safety profile of the oral iron chelator deferiprone. Br J Heamatol 108: 305-312, 2000.
162 Vesley, S., Buchanan, G.R., Cohen, A., Raskob, G., George, J. : Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: Results of a survey of practicing pediatric hematology-oncology specialists. J Pediat Hematol Oncol 22: 55-61, 2000.
157 Wanless, I.R., Sweeney, G., Dhillon, A.P., Guido, M., Piga, A., Galanello, R., DeSanctis, V., Schwartz, E., Cohen, A.: Absence of deferiprone-induced hepatic fibrosis: A multi-center study. American Society of Hematology Annual Meeting, San Francisco, CA December 2000.
12e Cohen, A.R., Galanello, R., Piga, A., Gamberini, R., DeSanctis, V., Tricta, F.: Long-term safety and efficacy of the oral iron chelator deferiprone (Presentation). American Society of Hematology, San Francisco, CA December 2000.
2c